Vol. 6 No. 5 (2026): May
Reimbursement Reviews

Pegunigalsidase Alfa (Elfabrio)

decorative image of the issue cover

Published May 29, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Pegunigalsidase alfa (Elfabrio), 2 mg/mL, concentrate for solution (20 mg/10 mL and 5 mg/2.5 mL vial) for IV infusion.
  • Indication: Proposed: long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).